These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34529328)

  • 1. The Role of Spike Protein Mutations in the Infectious Power of SARS-COV-2 Variants: A Molecular Interaction Perspective.
    Gómez SA; Rojas-Valencia N; Gómez S; Cappelli C; Restrepo A
    Chembiochem; 2022 Apr; 23(7):e202100393. PubMed ID: 34529328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.
    Wang R; Chen J; Gao K; Wei GW
    Genomics; 2021 Jul; 113(4):2158-2170. PubMed ID: 34004284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
    Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data.
    Khan A; Zia T; Suleman M; Khan T; Ali SS; Abbasi AA; Mohammad A; Wei DQ
    J Cell Physiol; 2021 Oct; 236(10):7045-7057. PubMed ID: 33755190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility.
    Gan HH; Twaddle A; Marchand B; Gunsalus KC
    J Mol Biol; 2021 Jul; 433(15):167051. PubMed ID: 33992693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab
    Liu H; Wei P; Zhang Q; Chen Z; Aviszus K; Downing W; Peterson S; Reynoso L; Downey GP; Frankel SK; Kappler J; Marrack P; Zhang G
    MAbs; 2021; 13(1):1919285. PubMed ID: 34074219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective.
    Ibrahim IM; Elfiky AA; Elgohary AM
    Biochem Biophys Res Commun; 2021 Jul; 562():89-93. PubMed ID: 34049205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.
    Tsai MS; Shih WT; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
    Biomed Pharmacother; 2022 May; 149():112802. PubMed ID: 35279013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin converting enzyme 2).
    Istifli ES; Netz PA; Sihoglu Tepe A; Sarikurkcu C; Tepe B
    J Biomol Struct Dyn; 2022; 40(23):12760-12771. PubMed ID: 34495817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. South African (501Y.V2) and the United Kingdom (B.1.1.7) SARS-CoV-2 Spike (S) Protein Variants Demonstrate a Higher Binding Affinity to ACE2.
    Mohammad A; Abubaker J; Al-Mulla F
    Comb Chem High Throughput Screen; 2023; 26(3):589-594. PubMed ID: 35674297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines.
    Al-Zyoud W; Haddad H
    Biochimie; 2021 Dec; 191():91-103. PubMed ID: 34508827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
    Tsai MS; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
    Biomed Pharmacother; 2021 Oct; 142():112011. PubMed ID: 34388530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational decomposition reveals reshaping of the SARS-CoV-2-ACE2 interface among viral variants expressing the N501Y mutation.
    Socher E; Conrad M; Heger L; Paulsen F; Sticht H; Zunke F; Arnold P
    J Cell Biochem; 2021 Dec; 122(12):1863-1872. PubMed ID: 34516024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: insights from molecular dynamics simulations.
    Wu J; Zhang HX; Zhang J
    Phys Chem Chem Phys; 2023 Jan; 25(3):2304-2319. PubMed ID: 36597957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.
    Chakraborty C; Sharma AR; Bhattacharya M; Agoramoorthy G; Lee SS
    mBio; 2021 Aug; 12(4):e0114021. PubMed ID: 34465019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
    Zhang L; Cui Z; Li Q; Wang B; Yu Y; Wu J; Nie J; Ding R; Wang H; Zhang Y; Liu S; Chen Z; He Y; Su X; Xu W; Huang W; Wang Y
    Commun Biol; 2021 Oct; 4(1):1196. PubMed ID: 34645933
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.